Seeking Alpha

Weaker-than-expected Q1 results weigh on shares of ViroPharma (VPHM -9.5%), which has already...

Weaker-than-expected Q1 results weigh on shares of ViroPharma (VPHM -9.5%), which has already dropped nearly 30% in the past month as what has been the drug devloper’s biggest seller, Vancocin, faces potential generic competition. Citing the generic threat, VPHM cuts its 2012 revenue target by nearly 25%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|